Markets
markets

Nike stays green after tariff block rekindles some supply chain optimism

Nike shares spiked as much as 5.5% higher yesterday in after-hours trading after a federal court blocked most of President Trump’s proposed tariffs, a potential relief for brands like Nike that rely heavily on Asian manufacturing. Upon market open, the sneaker maker was only slightly up as Wall Street comes to terms with the idea that the White House likely has workarounds to keep tariffs in place.

The athletic giant has lost more than a third of its value over the past year amid cooling demand and tariff turmoil. About 18% of Nike’s footwear is made in China, while Vietnam accounts for about 50%. The company had warned that tariffs on Chinese and Mexican imports could drag on gross margins by up to five percentage points and planned price hikes by June 1 to offset rising costs. With tariffs on pause, that pressure could ease… at least for now.

Nike’s stock is down about 18% year to date.

More Markets

See all Markets
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most-searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be short hand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January more people in the US are searching for Eli Lilly’s weight loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides," a catch-all term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly's diabetes and weight loss drugs have outsold Novo's and that gap is expected to widen this year.

markets

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets, for instance bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.